阿托伐他联合曲美他嗪对冠心病患者血脂、炎性因子及心功能的影响

Influence of atorvastatin combined trimetazidine on levels of blood lipids,inflammatory factors and cardiac function in patients with coronary heart disease

目的:研究与分析阿托伐他汀联合曲美他嗪对冠心病(CHD)患者血脂、炎性因子与心功能的影响。方法:选择自2015年5月起至2016年10月于我院接受治疗的CHD患者128例,根据随机数字表法随机均分为曲美他嗪组(在常规治疗基础上接受曲美他嗪治疗)和联合治疗组(在曲美他嗪组基础上加用阿托伐他汀),疗程均为3个月。测量比较两组治疗前后血脂、炎性因子水平以及心功能。结果:与曲美他嗪组比较,联合治疗组治疗后甘油三酯[(2.11±0.73)mmol/L比(1.83±0.77)mmol/L]、总胆固醇[(5.14±0.96)mmol/L比(4.35±0.73)mmol/L]、低密度脂蛋白-胆固醇[(2.35±0.68)mmol/L比(1.90±0.34)mmol/L]、N末端B型利钠肽前体[(296.61±28.96)pg/ml比(187.53±32.63)pg/ml]、纤维蛋白原[(4.44±0.34)g/L比(3.63±0.54)g/L]、高敏C反应蛋白水平[(2.41±0.96)mg/L比(1.96±0.82)mg/L]、左室舒张末内径[(59.25±6.17)mm比(48.43±4.28)mm]和左室后壁厚度[(11.01±1.08)mm比(9.05±1.04)mm]降低更显著,高密度脂蛋白-胆固醇水平[(1.32±0.25)mmol/L比(1.47±0.38)mmol/L]和左室射血分数[(41.28±7.04)%比(48.66±7.54)%]升高更显著,P<0.05或<0.01。结论:冠心病患者使用阿托伐他汀联合曲美他嗪进行治疗后,其血脂、炎性因子水平,心功能、心脏结构均显著改善,效果显著,值得推广。

Objective： To study and analyze the influence of atorvastatin combined trimetazidine on levels of blood lipids, inflammatory factors and cardiac function in patients with coronary heart disease （CFID）. Methods： A total of 128 CHD patients treated in our hospital from May 2015 to Oct 2016 were selected. According to random number table, they were randomly and equally ：divided into trimetazidine group （received trimetazidine based on routine treatment） and combined treatment group （received atorvastatin based on trimetazidine group）. Both groups were treated for three months.Levels of blood lipids, inflammatory factors and cardiac function were measured and compared between two groups before and after treatment. Results： Compared with trimetazidine group after treatment, there were significant reductions in levels of triglyceride [ （2. 11 ± 0.73） mmol/L vs. （1.83 ± 0. 77） mmol/L], total cholesterol [ （5.14 ± 0.96） mmol/L vs. （4. 35±0. 73） mmol/L], low density lipoprotein cholesterol [ （2.35 ± 0. 68） mmol/L vs. （1.90 ± 0. 34） mmol/L], N terminal pro B type natriuretic peptide [- （296. 61 ± 28. 96） pg/ml vs. （187. 53 ± 32.63） pg/ml], fibrinogen [ （4. 44 -± 0.34） g/L vs. （3. 63 ± 0. 54） g/L] and high sensitive C reactive protein [ （2. 41 ± 0.96） mg/L vs. （1.96 ±0.82） mg/L], left ventricular end-diastolic dimension [（59.25 ± 6. 17） mm vs. （48. 43 ± 4. 28） mm] and left ventricular posterior wall thickness [（11.01±1.08） mm vs. （9. 05±1.04） mm], and significant rise in level of high density lipoprotein cholesterol [ （1.32 ± 0. 25） mmol/L vs. （1.47 ± 0.38） mmol/L] and left ventricular ejection fraction [ （41.28 ±7. 04）% vs. （48. 66±7. 54）%] in combined treatment group, P〈0. 05 or 〈0. 01. Conclusion： Atorvastatin combined trimetazidine can significantly improve blood lipid, inflammatory factor levels, cardiac function and cardiac structure in CHD patients. The therapeutic effect is significant, which is worth extending.